<p>Pembrolizumab is a programmed death receptor-1 (PD-1)-blocking antibody indicated:<br />
<br />
<strong>Melanoma</strong>:</p>

<ul>
	<li>for the treatment of patients with unresectable or metastatic melanoma.</li>
	<li>for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection.</li>
</ul>

<p><strong>Non-Small Cell Lung Cancer (NSCLC)</strong>:</p>

<ul>
	<li>in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations.</li>
	<li>in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC.</li>
	<li>as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) &ge;1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is: stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic.</li>
	<li>as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS &ge;1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving Pembrolizumab.</li>
</ul>

<p><strong>Small Cell Lung Cancer (SCLC)</strong>: for the treatment of patients with metastatic SCLC with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy.<br />
<br />
<strong>Head and Neck Squamous Cell Cancer (HNSCC)</strong>:</p>

<ul>
	<li>in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC.</li>
	<li>as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) &ge;1] as determined by an FDA-approved test.</li>
	<li>as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy.</li>
</ul>

<p><strong>Classical Hodgkin Lymphoma (cHL)</strong>: for the treatment of adult and pediatric patients with refractory cHL, or who have relapsed after 3 or more prior lines of therapy.<br />
<br />
<strong>Primary Mediastinal Large B-Cell Lymphoma (PMBCL)</strong>: for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy.&nbsp;<br />
<br />
<strong>Urothelial Carcinoma</strong>:</p>

<ul>
	<li>for the treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy and whose tumors express PD-L1 [Combined Positive Score (CPS) &ge;10] as determined by an FDA-approved test, or in patients who are not eligible for any platinum-containing chemotherapy regardless of PD-L1 status.</li>
	<li>for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.</li>
	<li>for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.</li>
</ul>

<p><strong>Microsatellite Instability-High Cancer</strong>: for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient. solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options, or colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.<br />
<br />
<strong>Gastric Cancer</strong>: for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) &ge;1] as determined by an FDA-approved test, with disease progression on or after 2 or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if appropriate, HER2/neu-targeted therapy.<br />
<br />
<strong>Esophageal Cancer</strong>: for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 [Combined Positive Score (CPS) &ge;10] as determined by an FDA-approved test, with disease progression after one or more prior lines of systemic therapy.<br />
<br />
<strong>Cervical Cancer</strong>: for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 [Combined Positive Score (CPS) &ge;1] as determined by an FDA-approved test.<br />
<br />
<strong>Hepatocellular Carcinoma (HCC)</strong>: for the treatment of patients with HCC who have been previously treated with sorafenib.<br />
<br />
<strong>Merkel Cell Carcinoma (MCC)</strong>: for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma.<br />
<br />
<strong>Renal Cell Carcinoma (RCC)</strong>: in combination with axitinib, for the first-line treatment of patients with advanced RCC.<br />
<br />
<strong>Endometrial Carcinoma</strong>: in combination with lenvatinib, for the treatment of patients with advanced endometrial carcinoma that is not MSI-H or dMMR, who have disease progression following prior systemic therapy and are not candidates for curative surgery or radiation.</p>